JP2018535696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535696A5 JP2018535696A5 JP2018540229A JP2018540229A JP2018535696A5 JP 2018535696 A5 JP2018535696 A5 JP 2018535696A5 JP 2018540229 A JP2018540229 A JP 2018540229A JP 2018540229 A JP2018540229 A JP 2018540229A JP 2018535696 A5 JP2018535696 A5 JP 2018535696A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- represented
- fragment
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 23
- 125000003729 nucleotide group Chemical group 0.000 claims 23
- 108091026890 Coding region Proteins 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 125000006850 spacer group Chemical group 0.000 claims 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000015534 trkB Receptor Human genes 0.000 claims 5
- 108010064880 trkB Receptor Proteins 0.000 claims 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 5
- 102000001708 Protein Isoforms Human genes 0.000 claims 4
- 108010029485 Protein Isoforms Proteins 0.000 claims 4
- 230000002068 genetic effect Effects 0.000 claims 4
- 206010061323 Optic neuropathy Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 208000020911 optic nerve disease Diseases 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 208000026845 Cochlear disease Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 claims 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims 1
- 230000036770 blood supply Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003477 cochlea Anatomy 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 102000056115 human SYN1 Human genes 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 230000004963 pathophysiological condition Effects 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078299A JP7503590B2 (ja) | 2015-10-26 | 2022-05-11 | 遺伝子構築物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518911.1A GB2547179A (en) | 2015-10-26 | 2015-10-26 | Genetic construct |
| GB1518911.1 | 2015-10-26 | ||
| PCT/GB2016/053319 WO2017072498A1 (en) | 2015-10-26 | 2016-10-25 | Genetic construct |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078299A Division JP7503590B2 (ja) | 2015-10-26 | 2022-05-11 | 遺伝子構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535696A JP2018535696A (ja) | 2018-12-06 |
| JP2018535696A5 true JP2018535696A5 (enExample) | 2019-11-21 |
| JP7073264B2 JP7073264B2 (ja) | 2022-05-23 |
Family
ID=55130230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540229A Active JP7073264B2 (ja) | 2015-10-26 | 2016-10-25 | 遺伝子構築物 |
| JP2022078299A Active JP7503590B2 (ja) | 2015-10-26 | 2022-05-11 | 遺伝子構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078299A Active JP7503590B2 (ja) | 2015-10-26 | 2022-05-11 | 遺伝子構築物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10342880B2 (enExample) |
| EP (2) | EP3368678B1 (enExample) |
| JP (2) | JP7073264B2 (enExample) |
| KR (1) | KR102819739B1 (enExample) |
| CN (1) | CN108350467B (enExample) |
| AU (1) | AU2016344508B2 (enExample) |
| CA (1) | CA3001036A1 (enExample) |
| CY (1) | CY1124588T1 (enExample) |
| DK (1) | DK3368678T3 (enExample) |
| ES (1) | ES2886009T3 (enExample) |
| GB (1) | GB2547179A (enExample) |
| HR (1) | HRP20211407T1 (enExample) |
| HU (1) | HUE056911T2 (enExample) |
| LT (1) | LT3368678T (enExample) |
| MX (1) | MX2018005286A (enExample) |
| PL (1) | PL3368678T3 (enExample) |
| PT (1) | PT3368678T (enExample) |
| RS (1) | RS62460B1 (enExample) |
| RU (1) | RU2734678C2 (enExample) |
| SI (1) | SI3368678T1 (enExample) |
| SM (1) | SMT202100520T1 (enExample) |
| WO (1) | WO2017072498A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3355938B1 (en) | 2015-10-01 | 2024-02-07 | Goleini Inc. | Targeted expression of chloride channels and methods of use thereof |
| GB201705484D0 (en) * | 2017-04-05 | 2017-05-17 | Quethera Ltd | Genetic construct |
| US20200263196A1 (en) * | 2017-09-27 | 2020-08-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising active cells |
| EP3697916A4 (en) | 2017-10-20 | 2021-08-11 | Research Institute at Nationwide Children's Hospital | METHODS AND MATERIALS FOR NT-3 GENE THERAPY |
| US20200399656A1 (en) * | 2017-12-05 | 2020-12-24 | University Of Washington | Compositions and methods for enhancing functional expression of therapeutic genes in photoreceptors |
| CN108250288A (zh) * | 2018-01-17 | 2018-07-06 | 吉林省农业科学院 | 一种叶绿体表达的脑源性神经营养因子hBDNFb蛋白及其制备方法 |
| CN109022487A (zh) * | 2018-08-15 | 2018-12-18 | 上海市第人民医院 | 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物 |
| EP3863605A4 (en) * | 2018-10-11 | 2022-10-26 | Decibel Therapeutics, Inc. | AAV1 VECTORS AND THEIR USES IN TREATMENT OF OTIC INDICATIONS |
| KR20210105382A (ko) * | 2018-12-19 | 2021-08-26 | 베르사멥 아게 | 단백질을 코딩하는 rna |
| WO2020179844A1 (ja) * | 2019-03-04 | 2020-09-10 | 公益財団法人東京都医学総合研究所 | Trk断片をコードする核酸構築物、及びその利用 |
| AU2020231228A1 (en) * | 2019-03-06 | 2021-09-02 | Generation Bio Co. | Closed-ended DNA (ceDNA) and immune modulating compounds |
| AU2020248101A1 (en) * | 2019-03-27 | 2021-09-16 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for factor VII therapy |
| JP2022536692A (ja) | 2019-06-11 | 2022-08-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達 |
| AU2020314866A1 (en) * | 2019-07-18 | 2022-02-03 | Lysogene | Compositions and methods for the treatment of Sanfilippo disease and other disorders |
| RU2719013C1 (ru) * | 2019-09-25 | 2020-04-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Генно-инженерная конструкция для стимуляции посттравматической регенерации периферических нервов |
| AU2020357740A1 (en) | 2019-09-30 | 2022-04-28 | Eli Lilly And Company | Adeno-associated virus (AAV) systems for treatment of genetic hearing loss |
| EP4048800A1 (en) | 2019-10-23 | 2022-08-31 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| CN116829595A (zh) | 2020-12-16 | 2023-09-29 | 武田药品工业株式会社 | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 |
| US20250018058A1 (en) * | 2021-02-26 | 2025-01-16 | Icahn School Of Medicine At Mount Sinai | Method for decreasing degeneration of retinal ganglion cells |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| CN118256562A (zh) * | 2022-12-26 | 2024-06-28 | 科辉智药(深圳)新药研究中心有限公司 | 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用 |
| KR20250142340A (ko) | 2023-02-02 | 2025-09-30 | 퀘세라 리미티드 | 재조합 아데노-부속 바이러스 벡터 |
| CN118534135A (zh) * | 2024-06-07 | 2024-08-23 | 中国人民解放军联勤保障部队第九二四医院 | 一种中枢性肥胖抵抗标志物及其检测方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229500A (en) | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| ATE258804T1 (de) * | 1996-10-16 | 2004-02-15 | Regeneron Pharma | Verfahren zur verabreichung von wachstumsfaktoren |
| AU3418199A (en) * | 1998-04-20 | 1999-11-08 | Koninklijke Nederlandse Akademie Van Wetenschappen | Use of viral vectors for treatment of the injured peripheral and central nervoussystem |
| IL156427A0 (en) * | 2000-12-19 | 2004-01-04 | Res Dev Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| US7060429B2 (en) * | 2001-02-22 | 2006-06-13 | University Of Maryland, Baltimore | Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
| FR2906533B1 (fr) * | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| US9265843B2 (en) * | 2008-03-27 | 2016-02-23 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor |
| CN103614416B (zh) * | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
-
2015
- 2015-10-26 GB GB1518911.1A patent/GB2547179A/en not_active Withdrawn
-
2016
- 2016-10-25 WO PCT/GB2016/053319 patent/WO2017072498A1/en not_active Ceased
- 2016-10-25 DK DK16788748.8T patent/DK3368678T3/da active
- 2016-10-25 SM SM20210520T patent/SMT202100520T1/it unknown
- 2016-10-25 CA CA3001036A patent/CA3001036A1/en active Pending
- 2016-10-25 ES ES16788748T patent/ES2886009T3/es active Active
- 2016-10-25 CN CN201680062516.6A patent/CN108350467B/zh active Active
- 2016-10-25 KR KR1020187011772A patent/KR102819739B1/ko active Active
- 2016-10-25 EP EP16788748.8A patent/EP3368678B1/en active Active
- 2016-10-25 PL PL16788748T patent/PL3368678T3/pl unknown
- 2016-10-25 AU AU2016344508A patent/AU2016344508B2/en active Active
- 2016-10-25 SI SI201631325T patent/SI3368678T1/sl unknown
- 2016-10-25 HU HUE16788748A patent/HUE056911T2/hu unknown
- 2016-10-25 JP JP2018540229A patent/JP7073264B2/ja active Active
- 2016-10-25 MX MX2018005286A patent/MX2018005286A/es unknown
- 2016-10-25 HR HRP20211407TT patent/HRP20211407T1/hr unknown
- 2016-10-25 RU RU2018115760A patent/RU2734678C2/ru active
- 2016-10-25 US US15/762,089 patent/US10342880B2/en active Active
- 2016-10-25 EP EP21187396.3A patent/EP3985119A1/en active Pending
- 2016-10-25 RS RS20211108A patent/RS62460B1/sr unknown
- 2016-10-25 LT LTEPPCT/GB2016/053319T patent/LT3368678T/lt unknown
- 2016-10-25 PT PT167887488T patent/PT3368678T/pt unknown
-
2019
- 2019-06-10 US US16/436,676 patent/US11471539B2/en active Active
-
2021
- 2021-09-06 CY CY20211100785T patent/CY1124588T1/el unknown
-
2022
- 2022-05-11 JP JP2022078299A patent/JP7503590B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535696A5 (enExample) | ||
| RU2018115760A (ru) | Генетическая конструкция | |
| US20220331409A1 (en) | Factor ix gene therapy | |
| JP2019089787A5 (enExample) | ||
| JP2025039615A (ja) | 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法 | |
| AU2021236481A1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| IL320714A (en) | Gene therapy for limb-girdle muscular dystrophy type 2c | |
| RU2019126509A (ru) | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе | |
| CN112029773B (zh) | 编码bdnf的核酸及其应用 | |
| UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| TW202033768A (zh) | 腺相關病毒對cln6聚核苷酸的遞送 | |
| JP2023526892A (ja) | バルデー・ビードル症候群の遺伝子治療 | |
| MX2024009478A (es) | Métodos para tratar enfermedades neovasculares oculares con variantes de aav2 que codifican aflibercept | |
| MX2023012410A (es) | Metodos para tratar enfermedades oculares usando variantes de aav2 que codifican aflibercept. | |
| EP4198047A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
| MX2022002960A (es) | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. | |
| WO2025010334A3 (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
| MX2024010002A (es) | Metodo para reducir la fluctuacion del cst en amd neovascular mediante un virus adenoasociado recombinante | |
| NZ748736B2 (en) | Treatment of complement-mediated disorders | |
| HK40077196A (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| HK40119673A (en) | Adeno-associated virus virions with variant capsid and methods of use thereof | |
| KR20240137067A (ko) | 개선된 심장 형질도입 및 간의 탈표적화를 위한 aav 캡시드 | |
| JP2024511851A (ja) | 改変血漿凝固第viii因子およびその使用方法 | |
| AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| HK40035863B (en) | Adeno-associated virus virions with variant capsid and methods of use thereof |